NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $589,874 | -19.2% | 75,049 | +2.7% | 0.00% | 0.0% |
| Q2 2023 | $729,829 | +112702.0% | 73,056 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $647 | -16.7% | 72,812 | +2.9% | 0.00% | 0.0% |
| Q4 2022 | $777 | -99.9% | 70,767 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $913,000 | +14.3% | 70,090 | +11.2% | 0.00% | 0.0% |
| Q2 2022 | $799,000 | +70.4% | 63,039 | +88.1% | 0.00% | 0.0% |
| Q1 2022 | $469,000 | -49.3% | 33,511 | +4.9% | 0.00% | 0.0% |
| Q4 2021 | $925,000 | -0.6% | 31,938 | +2.8% | 0.00% | 0.0% |
| Q3 2021 | $931,000 | +17.7% | 31,074 | +4.2% | 0.00% | 0.0% |
| Q2 2021 | $791,000 | +5.0% | 29,816 | +23.1% | 0.00% | 0.0% |
| Q1 2021 | $753,000 | +97.1% | 24,215 | +108.3% | 0.00% | 0.0% |
| Q4 2020 | $382,000 | +15.1% | 11,623 | +22.2% | 0.00% | 0.0% |
| Q3 2020 | $332,000 | – | 9,513 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |